Corpus Intelligence IC Memo — ACADIA VERMILION HOSPITAL 2026-04-26 12:47 UTC
IC Memo — ACADIA VERMILION HOSPITAL
Investment Committee Memorandum | LA | 78 beds | Grade C | EBITDA uplift $1.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ACADIA VERMILION HOSPITAL

CCN 194044 | nan, LA | 78 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ACADIA VERMILION HOSPITAL is a 78-bed suburban community hospital in nan, LA with $17.6M in net patient revenue and a 7.3% operating margin. The hospital serves a payer mix of 3.3% Medicare, 15.4% Medicaid, and 81.3% commercial.

Thesis: Turnaround. Our ML models identify $1.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 7.3% to 14.7% (+736bps).

Net Revenue HCRIS$17.6M
Current EBITDA COMPUTED$1.3M
Operating Margin COMPUTED7.3%
Occupancy HCRIS77.7%
Revenue / Bed COMPUTED$226K
Net-to-Gross HCRIS35.6%
Distress Probability ML45.5%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
63
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 7.3% places it above the state median. Among 63 size-comparable peers (39-156 beds), the median margin is -4.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (39-156), prioritizing same-state peers. 63 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ACADIA VERMILION HOSPITAL (Target)LA78$17.6M7.3%
TERREBONNE GENERAL HEALTH SYSTLA139$230.6M-8.3%
OCHSNER MEDICAL CENTER - KENNELA115$193.8M-2.9%
ST. PATRICK HOSPITALLA100$189.4M-7.4%
OPELOUSAS GENERAL HOSPITALLA151$168.5M-12.7%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
OCHSNER MEDICAL CENTER -NORTHSLA150$107.3M-5.7%
IBERIA MEDICAL CENTERLA133$107.0M1.3%
SOUTHERN REGIONAL MEDICAL CORPLA64$97.3M-50.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$370K+210bp18mo
Cost to Collect4.5%2.5%$352K+200bp12mo
Denial Rate Reduction12.0%6.5%$349K+198bp12mo
A/R Days Reduction5200.0%3800.0%$214K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$370K
Cost to Collect
$352K
Denial Rate Reduction
$349K
A/R Days Reduction
$214K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.3M
Current EBITDA$1.3M
+ RCM Uplift+$1.3M
Pro Forma EBITDA$2.6M
Current Margin7.3%
Pro Forma Margin14.7%
WC Released (1x)$676K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.0M$21.5M10.81x61.0%
Base (11x exit)10.0x11.0x$2.0M$24.3M12.21x65.0%
Bull Case9.0x11.0x$1.8M$29.2M16.32x74.8%
Bull (12x exit)9.0x12.0x$1.8M$32.4M18.10x78.5%
Bear Case11.0x10.0x$2.2M$14.4M6.57x45.7%
Bear (11x exit)11.0x11.0x$2.2M$16.5M7.55x49.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 63 hospitals with 39-156 beds
  • Same-state prioritization (n=64)
  • Comp margins: P25=-28.5% / P50=-4.2% / P75=2.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.